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The apoptosis-promoting protein Par-4 has been shown
to be down-regulated in Ras-transformed NIH 3T3 fibro-
blasts through the Raf/MEK/ERK MAPK pathway. Be-
cause mutations of the ras gene are most often found in
tumors of epithelial origin, we explored the signaling
pathways utilized by oncogenic Ras to down-regulate
Par-4 in RIE-1 and rat ovarian surface epithelial (ROSE)
cells. We determined that constitutive activation of the
Raf, phosphatidylinositol 3-kinase, or Ral guanine nucle-
otide exchange factor effector pathway alone was not suf-
ficient to down-regulate Par-4 in RIE-1 or ROSE cells.
However, treatment of Ras-transformed RIE-1 or ROSE
cells with the MEK inhibitors U0126 and PD98059 in-
creased Par-4 protein expression. Thus, although onco-
genic Ras utilizes the Raf/MEK/ERK pathway to down-
regulate Par-4 in both fibroblasts and epithelial cells, Ras
activation of an additional signaling pathway(s) is re-
quired to achieve the same outcome in epithelial cells.
Methylation-specific PCR showed that the par-4 promoter
is methylated in Ras-transformed cells through a MEK-de-
pendent pathway and that treatment with the DNA meth-
yltransferase inhibitor azadeoxycytidine restored Par-4
mRNA transcript and protein levels, suggesting that the
mechanism for Ras-mediated down-regulation of Par-4 is
by promoter methylation. Support for this possibility is
provided by our observation that Ras transformation was
associated with up-regulation of Dnmt1 and Dnmt3 DNA
methyltransferase expression. Finally, ectopic Par-4 ex-
pression significantly reduced Ras-mediated growth in
soft agar, but not morphological transformation, high-
lighting the importance of Par-4 down-regulation in spe-
cific aspects of Ras-mediated transformation of epithelial
cells.
Proper development and tissue homeostasis are regulated in
part through a complex balance between cell proliferation and
cell death. Any disruption in the processes that control this
balance can lead to disease states such as autoimmunity, neu-
rodegenerative disorders, and cancer (1–3). Therefore, an un-
derstanding of the molecules involved in regulating cell death
is crucial for prevention and treatment of these diseases.
The par-4 (prostate apoptosis response-4) gene was identi-
fied originally in a cDNA screen for genes up-regulated in
prostate cancer cells that were induced to undergo apoptosis
(4). Par-4 is expressed ubiquitously in a variety of cell lines and
rat organs, suggesting a physiologically common function for
Par-4 in most cells (5). However, although staining of Par-4 has
been observed in terminally differentiated cells, consistent
with its role in apoptosis, Par-4 staining has also been seen in
areas enriched in stem cell populations, suggesting that Par-4
may possess additional functions that remain to be defined (5).
par-4 gene and protein expression has been found to be down-
regulated in Ras-transformed NIH 3T3 mouse fibroblasts and by
transient expression of activated H-Ras in human fibroblasts and
HeLa cervical carcinoma cells (6–8). The ras gene family encodes
small GTPases involved in regulation of cytoplasmic signaling
pathways in response to diverse extracellular signals. ras gene
point mutations of codons 12, 13, and 61 are found frequently in
human cancers and result in persistent activation of Ras due to
impaired GTPase activity (9, 10). A consequence of constitutive
Ras activation is downstream changes in gene expression, which
in turn act to modulate a variety of processes, including prolifer-
ation, differentiation, angiogenesis, and apoptosis (11). Under-
standing how Ras subverts death is critical to understanding the
role of Ras in cancer. Ras is known to cause a shift in the
growth/apoptosis balance to favor growth over death and in doing
so promotes cell proliferation (12). Ras achieves growth-favoring
conditions in part by altering the expression of pro-apoptotic
genes to promote tumorigenesis. Thus, oncogenic Ras protects
cells from apoptosis by modulation of a variety of apoptosis-
related proteins, including down-regulation of Par-4 expression
(6, 7). Consistent with this possibility, transient Par-4 expression
causes an apoptotic response in Ras-transformed NIH 3T3
cells (7).
Ras mediates its actions by interaction with multiple down-
stream effectors, with the best characterized being the Raf
serine/threonine kinases (11, 13). Ras binds to and activates
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MEK2, which then activate the ERK1 and ERK2 MAPKs. The
downstream consequences of this signaling pathway that are
important in regulating cell survival are not clearly defined
(14). The second best characterized effector of Ras is phosphati-
dylinositol 3-kinase (PI3K), a lipid kinase that facilitates the
conversion of phosphatidylinositol 4,5-bisphosphate to phos-
phatidylinositol 3,4,5-triphosphate (15, 16). In turn, phosphati-
dylinositol 3,4,5-triphosphate promotes activation of the Akt/
protein kinase B serine/threonine kinase pathway and a cell
survival pathway (17). Phosphatidylinositol 3,4,5-triphosphate
can also activate guanine nucleotide exchange factors (e.g. Sos
and Vav) that activate the Rac small GTPase (18, 19), and a
prosurvival function for Rac has been described (20). Rac can
activate the JNK and p38 MAPKs, which are also activated by
apoptosis-inducing stimuli (21, 22). Although Raf and PI3K
represent the most studied effectors of Ras, other less well
understood effectors such as the guanine nucleotide exchange
factors (GEFs) for the Ral small GTPases (23) and the pro-
apoptotic NORE1/RASSF1 family proteins (24) may also facil-
itate the ability of Ras to regulate cell survival and apoptosis.
Previous analyses of Ras-transformed NIH 3T3 cells have
provided some indication of the mechanism of Par-4 down-
regulation by Ras (6–8). Activated H-Ras was shown to down-
regulate Par-4 through the ERK MAPK pathway based in part
on studies demonstrating that stable expression of activated
Raf-1, MEK1, or ERK2 in NIH 3T3 cells causes down-regula-
tion of Par-4 expression, whereas treatment with the MEK
inhibitor PD98059 blocks Ras-mediated loss of Par-4. In con-
trast, activated PI3K alone does not cause down-regulation of
Par-4 expression, and inhibition of PI3K does not restore Par-4
expression in Ras-transformed NIH 3T3 cells. In addition, ec-
topic expression of Par-4 was shown to block Ras-mediated
growth transformation, to inhibit tumor development, and to
induce apoptosis in transient assays by inhibiting NF-B (6–
8). Thus, these observations support an important contribution
of loss of Par-4 expression in Ras-mediated transformation and
that Raf is the key effector utilized by Ras to mediate Par-4
down-regulation in rodent fibroblasts.
Although rodent fibroblast cell lines are transformed
readily by activated Ras or Raf, we (25, 26) and others (27–
29) have shown that a variety of epithelial cell types (RIE-1,
IEC-6, MCF-10A, and human embryonic kidney (HEK)) are
transformed by Ras, but not by Raf. Instead, activation of Ral
GEF alone is sufficient to mediate Ras transformation of
human fibroblasts and epithelial cells (25). Thus, the signal-
ing cascades that promote Ras transformation exhibit impor-
tant cell type differences (11). Therefore, we initiated studies
to determine the mechanism by which Ras causes down-
regulation of Par-4 and to assess the importance of Par-4 in
Ras-mediated transformation of epithelial cells. We found
that, although activation of the Raf/MEK/ERK pathway is
necessary for par-4 down-regulation, activated Raf alone is
not sufficient to mediate this process. We also show that the
decrease in Par-4 transcript levels is due to promoter silenc-
ing through DNA hypermethylation. Importantly, Ras-medi-
ated soft agar growth (but not morphological transformation)
was significantly impaired upon ectopic Par-4 expression,
demonstrating that down-regulation of Par-4 is a necessary
prerequisite for specific aspects of Ras-mediated transforma-
tion of epithelial cells.
MATERIALS AND METHODS
Cell Lines and Constructs—pBabe-puro and pZIP-NeoSV(x)1 retro-
virus expression vectors for activated Ras, Raf-1, the p110 catalytic
subunit (p110-CAAX), and Ral GEF (Rlf-CAAX) have been described
previously (26, 30). A mammalian expression vector containing the
cDNA sequence encoding Par-4 was generated by subcloning a 1.4-kb
EcoRI fragment from pCB6/Par-4 into pBabe-puro (pBabe-Par-4). NIH
3T3 mouse fibroblasts stably transfected with the pZIP-NeoSV(x)1
empty expression vector or pZIP-H-ras(61L) were maintained in Dul-
becco’s modified Eagle’s medium supplemented with 10% calf serum as
described previously (26). 208F rat fibroblasts stably transfected with
the pBabe-puro empty expression vector or pBabe-H-ras(12V) were
maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum (FCS) as described (4). RIE-1 (rat intestinal epi-
thelial) cells stably transfected with the pZIP-NeoSV(x)1 empty vector
or pZIP-K-ras(12V) were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 5% FCS as described previously (26). Rat
ovarian stromal epithelial (ROSE) cell lines stably transfected with the
pBabe-puro empty vector, pZIP-H-ras(12V), or pZIP-K-ras(12V) were
maintained in Dulbecco’s modified Eagle’s medium containing 10% FCS
(31). HEK and human mammary epithelial cell lines stably infected
with the pBabe-puro empty vector or encoding FLAG epitope-tagged
H-ras(12V) were maintained in -minimal essential medium supple-
mented with 10% FCS or in MEM medium (Cambrex), respectively
(25, 32). The DLD-1 human colon adenocarcinoma cell line, which
harbors one endogenous mutant K-ras(13D) allele, and a derivative cell
line of DLD-1 lacking the mutant K-ras allele (DKO-3) were maintained
in RPMI 1640 medium supplemented with 10% FCS. The reduced
ability of the DKO-3 variant to form colonies in soft agar and tumors in
athymic nude mice has been described previously (33, 34).
Western Blot Analysis—Subconfluent exponentially growing cell cul-
tures were harvested in buffer containing 0.5 phosphate-buffered
saline, 0.5% Nonidet P-40, 50 mM sodium fluoride, 1 mM dithiothreitol,
1 mM phenylmethylsulfonyl fluoride, and 25 g/ml each aprotinin and
leupeptin. Protein concentrations were measured by the Lowry assay
(Bio-Rad). Unless noted otherwise, all blots were analyzed with 30 g of
soluble lysate separated on 12% SDS-polyacrylamide gels, transferred
to Immobilon-P membranes (Millipore Corp.), immunoblotted with rab-
bit anti-Par-4 polyclonal antibody (R-334, Santa Cruz Biotechnology,
Inc.) or mouse -actin monoclonal antibody (clone AC-15, Sigma), and
detected with horseradish peroxidase-conjugated anti-rabbit or anti-
mouse secondary antibody (Amersham Biosciences), respectively, by
enhanced chemiluminescence (ECL, Amersham Biosciences).
Pharmacological Inhibitors—The chemical inhibitors used in this
study were as follows: MEK1/2 inhibitors PD98059 (Calbiochem) and
U0126 (Promega Corp.), PI3K inhibitor LY294004 (Promega Corp.), p38
MAPK inhibitor SB203580 (Calbiochem), and JNK MAPK inhibitor
SP600125 (provided by J. K. Westwick, Celgene Corp.) (35).
RNA Isolation and Northern Blot Analysis—Total RNA from cul-
tured cells was isolated by the guanidine thiocyanate/acid/phenol
method (36). For Northern blot analyses, 25 g of total RNA was
size-fractionated on 1.4% formaldehyde gels, transferred to Hybond-N
nylon membrane (Amersham Biosciences), and hybridized to 32P-la-
beled DNA probes. The par-4 cDNA probe used was a fragment corre-
sponding to the 1.4-kb EcoRI insert from pCB6 (described above). Rat
plasmid cDNA clones for dnmt1, dnmt3a, and dnmt3b used for gener-
ating probes were kindly provided by Dr. E. Li (Harvard University).
Verification of equivalent loading of RNA was done by hybridization
with an oligonucleotide corresponding to the 28 S rRNA (Clontech).
Hybridization was carried out by incubation with 1  106 cpm/ml in
PerfectHyb Plus hybridization buffer (Sigma) at 68 °C for par-4 and
dnmt1 and at 40 °C for the 28 S rRNA oligonucleotide according to the
manufacturer’s recommendations.
DNA Methylation Analysis—To assess the role of DNA methylation
in Ras-mediated down-regulation of Par-4, cells were incubated in
growth medium supplemented with 2 M 5-aza-2-deoxycytidine
(Sigma) or Me2SO for 6 days. Azadeoxycytidine is an inhibitor of cyto-
sine methyltransferase that methylates CpG islands in genomic DNA
(37). Methylation patterns in the CpG island of par-4 were assessed by
chemical bisulfite modification as described previously (3). In this pro-
cedure, unmethylated (but not methylated) cytosines are converted to
uracil. Methylation-specific PCR was performed with primers specific
for either methylated or bisulfite-modified unmethylated DNA. DNA
methylation patterns in the CpG island of the par-4 gene were deter-
mined using multiple sets of primers. The primers specific for methyl-
ated DNA, which were designed based on DNA sequence information
(GenBankTM accession number AF503628) to target a CpG-rich region
4466 bp upstream of the transcription start site (5), were as follows:
GTTGGCGTAGGGTAGGTTGTAGC (forward) and GAAACACGAAC-
GAAAAAAACCGA (reverse). Those specific for unmethylated DNA
were as follows: GGTTGGTGTAGGGTAGGTTGTAGTG (foward) and
CCAAAACACAAACAAAAAAAACCAAA (reverse). PCR was optimized
for each primer pair. DNA treated in vitro with SssI methyltransferase
(New England Biolabs Inc.) was used as positive control for methylated
DNA and that from normal lymphocytes was used as a negative control
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for unmethylated DNA in PCR with the methylation-specific par-4
primers.
For sample preparation, 1 g of DNA isolated from HEK cells stably
expressing vector or activated Ras was denatured by NaOH and mod-
ified by sodium bisulfite. DNA samples were then purified using Wizard
DNA purification resin (Promega Corp.), again treated with NaOH,
precipitated with ethanol, and resuspended in water. PCRs without
DNA were performed as a control. Each PCR product (10–12 l) was
directly loaded onto nondenaturing 6% polyacrylamide gels or 4% aga-
rose gels consisting of 2% ultrapure agarose (Invitrogen) plus 2% Sea-
Plaque low melting agarose (BMA Products), stained with ethidium
bromide, and visualized under UV illumination.
Focus Formation and Soft Agar Colony Formation Assays—The abil-
ity of Par-4 to inhibit K-Ras(12V)-mediated focus formation was deter-
mined by cotransfection using Lipofectamine Plus (Invitrogen) and 50
ng of pZIP-K-ras(12V) with 0.5 ng of pBabe-Par-4 or empty vector, and
the appearance of transformed foci was quantified after 21 days in
culture. For photomicrographs, cells were fixed in 10% acetic acid and
10% methanol and stained in 0.4% crystal violet in 20% ethanol.
For soft agar analyses, mass populations of RIE-1 cells stably ex-
pressing K-Ras(12V) and Par-4 were established by cotransfection with
pZIP-K-ras(12V)(neor) and pBabe-Par-4(puror), followed by co-selection
in growth medium supplemented with 500 g/ml G418 and 1 g/ml
puromycin. To assess colony formation in soft agar, cells were seeded at
2  104/60-mm dish in growth medium containing 0.3% agar. Verifica-
tion that colonies were alive at the time of quantification was done by
staining with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (thiazolyl blue; Sigma) after 21 days in culture. 3-(4,5-Dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide is enzymatically con-
verted from a yellow soluble salt to an insoluble purple product in viable
(but not dead) cells (38). Briefly, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide was dissolved at 2 mg/ml in phosphate-buffered
saline, and 0.5 ml was washed gently over colonies on the dishes.
Colonies were counted and photographed after incubation at 37 °C for
15 min.
PCR Analyses—Reverse transcription was carried out with oligo(dT)
primers using Superscript II reverse transcriptase (Invitrogen) and 11 g
of total RNA as recommended by the manufacturer. Subsequent PCR
amplification for each transcript was with 200 M dNTPs, 1.5 mM MgCl2,
1 unit of AmpliTaq DNA polymerase (Roche Applied Science), 1 buffer
(supplied by the manufacturer), and 0.2 M each primer. Primer se-
quences were as follows: dnmt1, 5-CCAGATACCTACCGGTTATTCG-3
(sense) and 5-TCCTTTAACTGCAGCTGAGGC-3 (antisense); dnmt3a,
5-FCTGAAATGGAAAGGGTGTTTGGC-3 (sense) and 5-CCATGTC-
CCTTACACACAAGC-3 (antisense); dnmt3b, 5-GTACTTCTGGGGTA-
ACCTACC-3 (sense) and 5-GCAAACAGGTGTCTGATGACC-3 (anti-
sense); and -actin, 5-GACCCAGATCATGTTTGAGACC-3 (sense) and
5-AGTCCATCACAATGCCAGTGGT-3 (antisense). Amplification condi-
tions were as follows: one cycle at 94 °C for 3 min; 30 cycles at 94 °C for
30 s, 55 °C (for dnmt1 and -actin) or 65 °C (for dnmt3a and dnmt3b) for
30 s, and 72 °C for 1.5 min; and one cycle at 72 °C for 6 min.
RESULTS
Previous studies of the relationship between oncogenic Ras
transformation and Par-4 expression have focused primarily on
analyses in mouse fibroblasts. In these studies, expression of
oncogenic Ras resulted in nearly complete loss of detectable Par-4
protein expression (6–8). To assess the relationship between Ras
and Par-4 in epithelial cells, we examined Par-4 protein levels in
several Ras-transformed epithelial cell lines. As described previ-
ously for NIH 3T3 mouse fibroblasts (6–8), we observed that
208F rat fibroblasts expressing constitutively active K-Ras(12V)
also showed down-regulated Par-4 protein levels (Fig. 1). Simi-
larly, RIE-1, ROSE, HEK, and human mammary epithelial cells
expressing either activated H-Ras(12V) or K-Ras(12V) exhibited
a decrease in Par-4 protein expression (Fig. 1). Thus, Ras-medi-
ated transformation of a variety of epithelial cell types as well as
fibroblasts resulted in down-regulation of Par-4. Interestingly,
fibroblasts expressed less endogenous Par-4 compared with the
epithelial cells, suggesting that endogenous levels of Par-4 ex-
pression are cell type-dependent.
The reduced expression of Par-4 observed in response to the
forced expression of mutant Ras led us to investigate whether
a similar loss of Par-4 would occur in tumor cell systems with
endogenous aberrant Ras activity and thus more closely reveal
in vivo physiological oncogenic Ras conditions. To address this
question, we evaluated Par-4 protein levels in a human colon
tumor cell system in which oncogenic Ras was shown previ-
ously to be critical for tumorigenic transformation. Shirasawa
et al. (34) used homologous recombination to knock out the
single mutant K-ras(13D) allele present in DLD-1 human colon
carcinoma cells and determined that loss of oncogenic Ras
function results in a drastic impairment of their transformed
phenotype both in vitro and in vivo. As shown in Fig. 1B, the
DLD-1 colon tumor cell line, which harbors a naturally occur-
ring mutation in K-ras(13D), showed lower levels of Par-4
compared with its genetic variant (DKO-3) in which the mutant
K-ras allele was deleted. Thus, these data demonstrate that
decreased levels of Par-4 are associated with naturally occur-
ring aberrant Ras activity, suggesting that loss of Par-4 is an
important event in the tumorigenesis of cells that display ab-
normal Ras function.
Because we observed that down-regulation of Par-4 protein
levels is correlated with Ras transformation of multiple cell
types, we next investigated whether this reduction is biolog-
ically important to Ras-mediated transformation. Loss of an-
chorage and density dependence growth is a key growth
characteristic of tumor cells that distinguishes them from
normal cells. The ability of tumor cells to continue to prolif-
erate under conditions of confluency (density dependence)
and in the absence of substratum attachment (soft agar
growth) distinguishes tumor cells from normal cells (39).
First, we examined the ability of Par-4 to inhibit Ras-medi-
ated focus forming (density dependence) activity. In these
experiments, we transfected RIE-1 cells with an expression
vector encoding activated K-Ras(12V) either alone or to-
gether with Par-4 and evaluated the consequences of Par-4
expression on Ras focus forming activity. As shown in Fig. 2
FIG. 1. Par-4 expression is reduced in epithelial cells express-
ing oncogenic Ras. A, Par-4 protein expression is down-regulated in
Ras-transformed epithelial cells. Equal amounts of total protein lysate
from fibroblasts (NIH 3T3 and Rat-1) and epithelial cells (RIE-1, ROSE,
HEK, and human mammary (HMEC)) expressing constitutively active
Ras () or vector only () were analyzed for Par-4 expression by
Western blot analysis with anti-Par-4 antiserum. B, loss of mutant
K-Ras is associated with elevation of Par-4 expression. Equal amounts
of total protein cell lysate from the human colon tumor cell lines DLD-1
(containing an activated K-ras(13D) allele) and DKO-3 (derivative of
DLD-1 with the mutant K-ras allele deleted) were analyzed for Par-4
expression by Western blot analysis with anti-Par-4 antiserum. To
control for loading, the membrane was stripped of the anti-Par-4 anti-
body and reblotted with anti-actin serum.
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(A and B), coexpression of Par-4 caused a 40% reduction in
Ras transforming activity compared with the activity caused
by cotransfection of the empty vector. These data suggest
that the elevated expression of Par-4 inhibits Ras-mediated
transformation and that down-regulation of Par-4 is a neces-
sary prerequisite for Ras-induced transformation.
To further evaluate how Par-4 antagonizes Ras transforma-
tion, we generated stable cell lines that ectopically express
Par-4 to determine whether re-expression of Par-4 could inhibit
or reverse Ras-mediated transformation. As shown in Fig. 3A,
forced ectopic Par-4 protein expression was restored to levels
similar to those seen in the control empty vector-transfected
cells, but there was no change or reversion in the morphological
transformation (Fig. 3B) compared with cells transfected with
the empty vector. However, when we compared their ability to
grow under anchorage-independent conditions, we found that
restoration of Par-4 expression reduced the ability of Ras-
transformed RIE-1 cells to grow in semisolid agar by 55% (Fig.
3, C and D). In addition, re-expression of Par-4 reduced not only
the number of colonies, but also the size of the colonies (Fig.
3E). Because Ras (but not Raf) results in down-regulation of
Par-4, we also examined whether forced expression of domi-
nant-negative Par-4 (40) in the Raf-expressing cells would
render these cells transformed. However, we observed no
change in morphology or ability to grow in soft agar (data not
shown). Thus, because forced re-expression of Par-4 inhibited
the soft agar growth of the Ras-transformed cells, we conclude
that the reduced expression of Par-4 observed in Ras-trans-
formed cells is biologically relevant and represents an impor-
tant mechanism by which Ras mediates transformation.
To investigate the mechanism by which Ras down-regulates
Par-4 in epithelial cells, we next evaluated the potential in-
volvement of several signaling pathways commonly activated
by Ras. Although the Raf/MEK/ERK MAPK pathway repre-
sents the most widely studied Ras effector pathway, other
pathways such as the PI3K/Akt and Ral GEF effector pathways
have also been shown to be important for Ras transformation
(11, 13). To determine whether activation of a specific effector
pathway alone is sufficient to down-regulate Par-4 expression,
we previously established ROSE cells stably expressing consti-
tutively active forms of Raf-1 (membrane-targeted Raf-CAAX
and N-terminally truncated Raf-22W), PI3K (p110-CAAX), and
Ral GEF (Rlf-CAAX) and verified that they cause activation of
ERK, Akt, and Ral-GTP, respectively (31). Activated Raf alone
is sufficient to cause partial growth transformation of ROSE
cells. In contrast to the reduced levels of Par-4 protein seen in
H-Ras(12V)-expressing ROSE cells (Fig. 4A), there were no
detectable reductions in Par-4 expression in ROSE cells ex-
pressing any one activated effector alone. Finally, similar to
our results in ROSE cells, activated Raf alone was insufficient
to cause loss of Par-4 expression in RIE-1 cells (Fig. 4A). There-
fore, our results in ROSE and RIE-1 cells are in contrast to
those described in fibroblasts, where Raf activation alone is
sufficient to down-regulate Par-4 expression (6–8). Thus, the
mechanism by which Ras down-regulates Par-4 in epithelial
cells requires activation of Raf-independent effector pathways.
To determine whether activation of a particular effector
pathway is necessary to cause down-regulation of Par-4, we
utilized several pharmacological inhibitors of MEK and PI3K
to assess the importance of these pathways in Ras down-regu-
lation of Par-4. Interestingly, we found that inhibition of ERK
activation in both Ras-expressing RIE-1 and ROSE cells by
treatment with the MEK inhibitors PD98059 and U0126 re-
stored the level of Par-4 expression to that seen in control
untransformed RIE-1 and ROSE cells (Fig. 4B). Inhibition of
MEK also reverses Ras-induced growth transformation of
RIE-1 (41) and ROSE (31) cells. In contrast, we found that the
p38 MAPK inhibitor SB203580, the PI3K inhibitor LY294002,
and the JNK inhibitor SP600125 had no effect on Par-4 expres-
sion. Thus, we conclude that, although activation of the ERK
pathway alone is not sufficient to recapitulate the signaling
cascade mediated by Ras to down-regulate Par-4, activation of
ERK by Ras does appear to be a necessary component.
Other signaling pathways utilized by Ras include those ac-
tivated by the Rho family of small GTPases, such as Rac1,
RhoA, and Cdc42, which can be activated by Ras. Ras-mediated
transformation of rodent fibroblasts has been shown to require
the function of these GTPases (42). Because Rho family GT-
Pases can either trigger cell death or promote cell survival
depending on the cellular context (43) and because Par-4 is a
known pro-apoptotic response protein, we sought to determine
whether Rac1 or other small GTPases such as RhoA and Cdc42
could also down-regulate Par-4. For these analyses, we utilized
mass populations of RIE-1 cells stably expressing constitu-
tively active Rac1(61L) or RhoA(63L) or activated forms of the
Dbl family proteins Vav and Dbl, which are GEFs and activa-
tors of Rho family GTPases (44). Vav is an activator of RhoA,
Rac1, and Cdc42, whereas Dbl is an activator of RhoA and
Cdc42 (45, 46). Although activated Ras down-regulated Par-4,
no change in Par-4 levels was observed with RhoA, Rac1, Vav,
or Dbl (data not shown), suggesting that Ras does not mediate
down-regulation of Par-4 through RhoA, Rac1, or Cdc42 in
RIE-1 cells.
We recently demonstrated that Ras-mediated transforma-
tion causes down-regulation of -tropomyosin gene expression
and that the mechanism is through promoter methylation (44).
Promoter methylation represents one common mechanism of
epigenetic gene silencing in human carcinomas (47). For exam-
ple, the expression of various tumor suppressor genes, includ-
ing BRCA1, E-cadherin, MLH1, p16, VHL, and RB1, is inacti-
vated by hypermethylation in many human cancers (48).
Therefore, we assessed the possibility that promoter methy-
lation is involved in oncogenic Ras suppression of Par-4
expression.
FIG. 2. Par-4 coexpression inhibits Ras-mediated focus forma-
tion. The ability of Par-4 to inhibit K-Ras(12V)-mediated focus forma-
tion was determined by cotransfection of 50 ng of pZIP-K-ras(12V) and
0.5 g of either pBabe-puro empty vector or pBabe-Par-4, and the
appearance of transformed cells as foci was quantified after 21 days in
culture. A, photomicrographs of transformed foci after staining with
crystal violet; B, quantitation of the average number of total foci from
triplicate plates. Data shown are representative of three independent
experiments and are expressed as the mean  S.D. of foci per plate.
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To determine whether loss of Par-4 expression is due to DNA
methylation, we first treated Ras-transformed RIE-1 cells with
the azadeoxycytidine demethylating agent and determined
whether Par-4 expression was restored. Azadeoxycytidine is a
specific inhibitor of DNA methyltransferase (49, 50) and has
been used widely to assess the role of methylation in promoter
silencing. As shown in Fig. 5A, Par-4 mRNA and protein ex-
pression was increased after treatment with azadeoxycytidine
compared with that in untreated Ras-expressing RIE-1 cells.
To extend these analyses, we also examined DNA methylation
of Par-4 in azadeoxycytidine-treated ROSE cells overexpress-
ing mutant Ras and in DLD-1 cells, which harbor an endoge-
nous mutant ras allele. As shown in Fig. 5B, azadeoxycytidine
treatment also caused an increase in Par-4 expression in both
ROSE and DLD-1 cells. Thus, these results demonstrate that
promoter methylation may be a general mechanism of Ras-
mediated down-regulation of Par-4.
Interestingly, azadeoxycytidine treatment also causes a par-
tial reversion of the morphological transformation of both Ras-
transformed RIE-1 (44) and ROSE (data not shown) cells, sup-
porting the importance of DNA methylation in Ras-mediated
transformation. To directly determine the methylation status
of the par-4 promoter, we analyzed DNA obtained from Ras-
expressing or vector only-transfected HEK cells by methyla-
FIG. 3. Ectopic expression of Par-4 inhibits Ras-mediated
growth, but not morphological transformation. Mass populations
of RIE-1 cells stably cotransfected with pZIP-K-ras(12V) and pBabe-
Par-4 or the pBabe-puro empty vector alone were compared with control
cells transfected with each empty vector. A, Par-4 expression is restored
in Ras-transformed RIE-1 cells to levels seen in control RIE-1 cells.
Equal amounts of total protein cell lysate were analyzed for Par-4
expression by Western blot analysis with anti-Par-4 antiserum. To
control for loading, the anti-Par-4 antibody was stripped, and the mem-
brane was reblotted with anti-actin serum. B, increased Par-4 expres-
sion does not reverse the morphological transformation of K-Ras(12V)-
transformed RIE-1 cells (magnification 40). C, ectopic expression of
Par-4 inhibits Ras-mediated anchorage-independent growth of RIE-1
cells in soft agar. Ras-transformed RIE-1 cells stably overexpressing
FIG. 4. Ras activation of the Raf/ERK effector is necessary but
not sufficient to down-regulate Par-4 expression. A, activation of
the Raf, PI3K, or Ral GEF effector pathway alone is not sufficient to
cause down-regulation of Par-4. Equal amounts of total protein cell
lysate prepared from ROSE and RIE-1 cells stably expressing the
indicated proteins were analyzed for Par-4 expression by Western blot
analysis with anti-Par-4 antiserum. To control for loading, the anti-
Par-4 antibody was stripped, and the membrane was reblotted with
anti-actin serum. Lysates denoted as “-1,” “-2,” and “-3” represent du-
plicate stable cell lines generated at different times. B, inhibition of
MEK signaling restores Par-4 expression in Ras-transformed RIE-1
and ROSE cells. RIE-1 and ROSE cells stably expressing activated Ras
were maintained for 48 h in growth medium supplemented with 50 M
PD98059 (MEK1/2), 30 M U0126 (MEK1/2), 10 M SB203580 (p38), 10
M LY294002 (PI3K), or 20 M SP600125 (JNK). Equal amounts of total
protein cell lysate were analyzed for Par-4 expression by Western blot
analysis with anti-Par-4 antiserum. To control for loading, the anti-
Par-4 antibody was stripped, and the membrane was reblotted with
anti-actin serum. DMSO, dimethyl sulfoxide.
ectopic Par-4 were assayed for their ability to proliferate in growth
medium containing 0.3% agar and the formation of multicellular colo-
nies (magnification 40) after staining with 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide. D, quantification of transformed
cells as foci after 21 days in culture from triplicate plates. Data shown
are representative of three independent experiments and are expressed
as the mean  S.D. of the colony number per plate. E, 400 magnifi-
cation of the colonies formed in the dishes shown in C.
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tion-specific PCR (Fig. 5C). HEK cells were chosen because
more promoter DNA sequence is available for the human gene.
The region chosen for methylation-specific PCR analysis spans
an area of high CpG density 4466 bp upstream of the tran-
scription start site (5). As shown in Fig. 5C, par-4 DNA was
present in the unmethylated form in both vector only- and
Ras-expressing HEK cells. Importantly, the methylated form of
par-4 DNA was observed only in the Ras-expressing cells.
These data are consistent with our observed partial but not
complete down-regulation of Par-4 protein expression in the
Ras-expressing HEK cells (Figs. 1 and 4A). Because treatment
of the Ras-expressing HEK cells with MEK inhibitors restored
Par-4 protein expression, we next investigated whether the
mechanism for restored Par-4 expression is through a MEK-
dependent pathway, resulting in loss of DNA methylation of
the par-4 DNA promoter. As shown in Fig. 5C, the methylated
form of par-4 DNA was abolished in the Ras-expressing HEK
cells treated with U0126 compared with control vehicle-treated
cells. Taken together, these data show directly that expression
of mutant Ras results in MEK-dependent down-regulation of
Par-4 through CpG methylation of the par-4 DNA promoter.
Because Par-4 transcript levels were restored upon treat-
ment with azadeoxycytidine, we assessed whether Ras causes a
change in expression of three DNA methyltransferases in-
volved in CpG hypermethylation. Dnmt1 methylates hemi-
methylated DNA and is therefore believed to be responsible for
maintenance of methylation patterns. On the other hand,
Dnmt3a and Dnmt3b are thought to be responsible for de novo
methylation of previously unmethylated DNA. Thus, Dnmt3a
and Dnmt3b may function as initiators of changes in DNA
methylation patterns (51), although the exact function of these
enzymes is presently not clear. To determine whether Ras
up-regulates the methyltransferases, we performed semiquan-
titative reverse transcription-PCR on mRNA isolated from
RIE-1 cells expressing Ras or the vector only. As shown in Fig.
6A, Ras-transformed RIE-1 cells showed an increase in both
dnmt1 and dnmt3a, but not dnmt3b. To further support this
finding, we performed Northern blot analyses and found that
dnmt1 was indeed increased in Ras-expressing cells (Fig. 6B).
We also tried to detect dnmt3a and dnmt3b; however, these
genes were below the level of detection. These results suggest
that Ras activation alone is sufficient to cause an increase in
the enzymes responsible for genomic DNA hypermethylation,
resulting in gene silencing of many genes, including par-4.
DISCUSSION
Emerging complexities of Ras signaling include the involve-
ment of Raf-independent effectors in mediating Ras transfor-
mation, cell type differences in Ras signaling, and the complex-
ity of genes deregulated in Ras-transformed cells (11). par-4
has been identified as a gene down-regulated by activation of
the Raf/ERK MAPK cascade in Ras-transformed fibroblasts
(6–8). In light of differences in the signaling pathways involved
in Ras transformation of fibroblasts versus epithelial cells, we
evaluated the mechanism and role of Par-4 down-regulation in
Ras transformation of epithelial cells. We found that Ras trans-
formation of a variety of epithelial cells was associated with
down-regulated Par-4 protein expression; that the Raf/ERK
pathway was necessary but not sufficient for Ras down-regu-
lation of Par-4 in rodent epithelial cells; that loss of Par-4
contributed to soft agar growth, but not morphological trans-
formation by Ras; and finally, that CpG DNA methylation
through a MEK-dependent pathway, possibly via up-regulation
of the Dnmt1 and Dnmt3a DNA methyltransferases, was in-
volved in suppression of par-4 gene expression.
Activated Ras and Raf show equivalent abilities to cause
transformation of NIH 3T3 and other rodent fibroblast cell
lines (26). In contrast, activated Ras (but not Raf) causes trans-
formation of RIE-1 rat intestinal and other epithelial cells
(25–29), thus demonstrating that the signaling cascades in
fibroblasts and epithelial cells, while similar, exhibit important
differences in signaling strategies and biological outcome (11).
Recent reports utilizing NIH 3T3 cells demonstrated that the
mechanism by which activated Ras causes down-regulation of
Par-4 is by signaling through the Raf/MEK/ERK MAPK path-
way (6–8). Therefore, we assessed the contribution of the ERK
MAPK and other signaling pathways to mediating Par-4 down-
FIG. 5. Par-4 expression is decreased through promoter meth-
ylation by Ras. A, azadeoxycytidine treatment reverses Ras-induced
down-regulation of Par-4. RIE-1 cells stably expressing K-Ras(12V)
were maintained in growth medium supplemented with 2 M azadeoxy-
cytidine for 6 days. Total RNA (25 g) from treated cells was size-
fractionated on formaldehyde-agarose gels and analyzed by Northern
blot analysis with 32P-labeled DNA probes for Par-4 or the 28 S riboso-
mal RNA as a loading control. Cell lysates from companion treated
cultures were used for Western blot analysis with anti-Par-4 antiserum.
To control for loading, the anti-Par-4 antibody was stripped, and the
membrane was reblotted with anti-actin serum. In parallel with the
restoration of Par-4 mRNA expression (upper panels), Par-4 protein
expression was restored after azadeoxycytidine treatment to levels
comparable to those seen in control vector only-expressing cells (lower
panels). B, azadeoxycytidine treatment of Ras-expressing ROSE and
DLD-1 cells enhances Par-4 expression. ROSE cells stably expressing
K-Ras(12V) and DLD-1 human colon tumor cells (which harbor an
endogenous mutant ras allele, K-ras(13D)) were treated with 2 M
azadeoxycytidine for 6 days, and protein lysates were used for Western
blot analysis with anti-Par-4 antiserum. To control for loading, the
anti-Par-4 antibody was stripped, and the membrane was reblotted
with anti-actin serum. C, par-4 promoter DNA is methylated in Ras-
transformed HEK cells. Primers specific for unmethylated (U) or meth-
ylated (M) DNA were used to amplify DNA from HEK cells expressing
the empty vector or H-Ras(12V) (left panel) or from Ras-expressing
HEK cells treated with vehicle alone (dimethyl sulfoxide (DMSO)) or
U0126 (30 M) for 6 days (right panel).
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regulation in Ras-transformed epithelial cells. We found that
the expression alone of constitutively active forms of three Ras
effectors (Raf, Ral GEF, and PI3K) was not sufficient to mimic
Ras-mediated down-regulation of Par-4 in epithelial cells.
These data suggest that, unlike in Ras-transformed rodent
fibroblasts, in which Par-4 is down-regulated via the Raf/ERK
pathway, in epithelial cells, activation of this pathway is not
sufficient to down-regulate Par-4. We recently found that two
other genes deregulated in Ras-transformed RIE-1 cells are
aberrantly expressed as a result of the combined concomitant
effects of two pathways. Expression of the actin-binding protein
tropomyosin is down-regulated in Ras-transformed RIE-1 cells
through a mechanism requiring activation of the Raf/MAPK
pathway along with inhibition of the p38 MAPK pathway (44).
Similarly, we also showed that the cell cycle regulatory protein
cyclin D1 is up-regulated in Ras-transformed cells through a
mechanism requiring activation of the Raf/ERK pathway to-
gether with inhibition of the p38 MAPK pathway (52). Thus, it
appears that, in epithelial cells, it is not uncommon to find Ras
utilizing a multiple-pathway approach to elicit a change in
gene expression.
Interestingly, however, although activation of the Raf/MAPK
pathway alone was not sufficient to down-regulate Par-4, inhi-
bition of MEK with the pharmacological inhibitors restored
Par-4 expression in Ras-transformed RIE-1 and ROSE cells.
This suggests that the Raf/ERK pathway represents one
branch in the pathway that Ras utilizes to down-regulate Par-4
and that inactivation of this branch alone is sufficient to dis-
rupt Ras-mediated down-regulation of Par-4. Thus, the clinical
utility of pharmacological drugs that target the Raf/MEK/ERK
pathway may inhibit tumor growth in part by restoring Par-4
expression and inhibition of transformation.
We determined that ectopic restoration of Par-4 expression
to levels found in untransformed cells caused a partial rever-
sion of Ras-mediated focus formation and soft agar growth of
RIE-1 cells. This observation is consistent with the previous
observation that Par-4 down-regulation contributes to growth
transformation of Ras-transformed NIH 3T3 rodent fibroblasts
(6–8). Similar to data observed in fibroblasts (6), we found that
restoration of Par-4 expression did not reverse the morpholog-
ical transformation of Ras-transformed RIE-1 cells. That Par-4
affects anchorage dependence and loss of density-dependent
growth (but not morphological transformation) is not unex-
pected and is consistent with the role of Par-4 as a regulator of
cell survival rather than a regulator of actin organization or
cell adhesion.
Promoter methylation represents a common mechanism uti-
lized by cancer cells to silence the expression of a variety of
genes (47). We showed recently that Ras down-regulates tro-
pomyosin through cytosine methylation of the promoter (44). In
addition, other studies have shown that oncogenic Ras-medi-
ated down-regulation of the genes encoding lysyl oxidase and
the Fas ligand is mediated by DNA methylation (53, 54). Sim-
ilarly, we have shown here that treatment of Ras-transformed
RIE-1, ROSE, and DLD-1 cells with azadeoxycytidine, a known
inhibitor of CpG methylation (37), restored Par-4 expression.
Interestingly, Barradas et al. (6) showed that, in NIH 3T3 cells,
Par-4 protein expression is not restored after treatment with
azadeoxycytidine. This discrepancy may be explained in part
by cell type differences. Barradas et al. used NIH 3T3 fibro-
blasts, whereas in this study, we utilized epithelial cells. In
addition, Barradas et al. treated the cells for only 2 days,
whereas we used a more extensive treatment time of 6 days. In
combination with our direct demonstration of promoter meth-
ylation using methylation-specific PCR, our data show that the
long-term mechanism for Ras-mediated loss of Par-4 expres-
sion involves CpG DNA hypermethylation, resulting in gene
silencing through aberrant cytosine methylation in epithelial
cells. In addition, the loss of methylation upon U0126 treat-
ment suggests that Ras utilizes a MEK-dependent pathway
leading to par-4 methylation. Finally, we observed that DNA
demethylation also caused a partial reversion of the morpho-
logical transformation in both Ras-expressing RIE-1 and ROSE
cells. Thus, promoter methylation and gene silencing of a va-
riety of tumor cell growth inhibitory genes, including par-4,
may be an important mechanism of Ras-mediated transforma-
tion for RIE-1, ROSE, and other epithelial cells.
The association of Ras and DNA methylation is highly inter-
twined. The DNA repair enzyme 6-O-methylguanine-DNA
methyltransferase functions to remove mutagenic and cyto-
toxic adducts from the position of guanine. If adducts such as
6-O-methylguanine are not removed, mispairing between the
6-O-methylguanine and thymine can occur during replication,
resulting in G-to-A mutations (55). In both colorectal and pan-
creatic carcinomas, the most prevalent ras mutations involve
FIG. 6. Dnmt1 and Dnmt3a DNA methyltransferase mRNA ex-
pression is up-regulated in Ras-transformed RIE-1 cells. Total
RNA from RIE-1 cells stably expressing K-Ras(12V) or the vector only
(A) along with cells expressing Raf-22W (B) was used for reverse tran-
scription-PCR analyses of Dnmt1, Dnmt3a, Dnmt3b, and -actin
mRNA levels (A) or for Northern blot analysis with 32P-labeled DNA
probes for Dnmt1 and the 18 S ribosomal RNA as a loading control (B).
In A, control PCRs (Mock) were performed without template cDNA to
show specificity of PCR products.
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G-to-A mutations at codons 12 and 13 (56). Esteller et al. (55)
showed that 71% of colorectal tumors exhibiting G-to-A muta-
tions in K-ras show loss of 6-O-methylguanine-DNA methyl-
transferase expression. In addition, their study found that loss
of 6-O-methylguanine-DNA methyltransferase occurs in small
adenomas that do not yet harbor K-ras mutations, further
supporting the idea that loss of the DNA repair function of
6-O-methylguanine-DNA methyltransferase results in the ac-
cumulation of K-ras mutations. In turn, Ras activation has
been shown in several studies to cause up-regulation of the
DNA methyltransferase Dnmt1. In one study, Ras-transformed
IEC-18 rat intestinal epithelial cells showed increased DNA
methyltransferase activity and methylation of the p16 tumor
suppressor gene, and treatment with azadeoxycytidine re-
sulted in the restoration of p16 expression (57). In another
study, inhibition of Ras activity in the Y1 mouse adrenocortical
tumor cell line, which overexpresses wild-type K-Ras by 30-
fold, resulted in a 50-fold decrease in DNA methyltransferase
enzyme activity and mRNA expression (58). In addition, injec-
tion of dnmt1 antisense oligodeoxynucleotides into Y1 mouse
tumors inhibits tumor growth (49). Our studies now show that,
in addition to up-regulating the Dnmt1 DNA methylation
maintenance enzyme, Ras also up-regulates the Dnmt3a
de novo DNA methylation enzyme. Taken together, these stud-
ies suggest a dependence of Ras-mediated tumor formation on
gene silencing through DNA methylation by a mechanism that
involves up-regulation of Dnmt1 and Dnmt3a. Additional stud-
ies to determine the mechanism by which Ras initiates up-
regulation of Dnmt1 and Dnmt3a will further our understand-
ing of how Ras causes down-regulation of certain genes (such as
par-4) that function to inhibit tumor growth.
In summary, our analyses of Ras-mediated down-regulation
of Par-4 support a model in which, in epithelial cells, oncogenic
Ras activation of ERK along with a yet unidentified pathway(s)
results in down-regulation of Par-4 by causing an increase in
the expression of CpG methyltransferases. The methylation of
promoters of key genes such as par-4 may then result in down-
regulation of their expression and thus contribute to the proc-
ess of transformation. The altered expression of many genes is
observed in Ras-transformed cells, and an important goal of
future studies will be to identify those that facilitate, rather
than simply correlate with, Ras transformation and those that
are mediated by changes in DNA methylation.
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